In our final episode of our first season, we chatted with John Evans, CEO of Beam Therapeutics. Our conversation spans lessons in commercializing therapies across the development life cycle, programmable gene editing platforms, evaluating biopharma partnerships, future trends in gene therapy accessibility, and more.

Beam Therapeutics is a leader in the nascent gene editing space, pioneering proprietary base editing to develop precision genetic medicines. In January 2022, Beam entered a $300M+ research collaboration with Pfizer. Beam Therapeutics is based in Cambridge, MA.